<DOC>
	<DOC>NCT01899105</DOC>
	<brief_summary>This study is designed to investigate the effect of food on the relative bioavailability of 2 different strengths of fixed-dose combinations of lumacaftor and ivacaftor tablet formulations.</brief_summary>
	<brief_title>A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor</brief_title>
	<detailed_description />
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Healthy male and female subjects as defined in the protocol Subjects who weigh &gt;50 kg at Screening History of any illness or condition that might confound the results of the study or pose an additional risk to the subject upon administration of study drug Positive for hepatitis B,C, or HIV Standard 12lead ECG demonstrating QTc &gt;450 msec for male subjects and &gt;480 msec for female subjects at the Screening Visit Abnormal renal function as defined in the protocol at Screening Forced expiratory volume in 1 second (FEV1) &lt;80% predicted at the Screening Visit Blood donation (of approximately 1 pint [500 mL] or more) within 56 days before the first dose of study drug Treatment with an investigational drug or device within 30 days or 5 halflives preceding the first dose of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>